Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, Lotan Y, Shariat SF, Zuiverloon TCM, Mir MC, van Rhijn BWG. Claps F, et al. Among authors: pouessel d. World J Urol. 2021 Dec;39(12):4363-4371. doi: 10.1007/s00345-021-03776-5. Epub 2021 Jul 1. World J Urol. 2021. PMID: 34196758 Free article.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S. Pouessel D, et al. Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21. Clin Genitourin Cancer. 2017. PMID: 27554584
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.
Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S. Sroussi M, et al. Among authors: pouessel d. Clin Genitourin Cancer. 2020 Aug;18(4):295-303.e3. doi: 10.1016/j.clgc.2019.11.014. Epub 2019 Dec 5. Clin Genitourin Cancer. 2020. PMID: 31882335
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. van Rhijn BWG, et al. Among authors: pouessel d. Eur Urol. 2020 Nov;78(5):682-687. doi: 10.1016/j.eururo.2020.07.002. Epub 2020 Jul 15. Eur Urol. 2020. PMID: 32682615
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
Sirab N, Drubay D, Maillé P, Popova T, Ngo C, Gentien D, Moktefi A, Soyeux-Porte P, Pelletier R, Reyes C, Henry E, Pouessel D, Vordos D, Lebret T, de Reyniès A, Paoletti X, Radvanyi F, Allory Y. Sirab N, et al. Among authors: pouessel d. J Pathol. 2022 Jan;256(1):108-118. doi: 10.1002/path.5813. Epub 2021 Nov 9. J Pathol. 2022. PMID: 34611919
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Mertens LS, et al. Among authors: pouessel d. Urol Oncol. 2022 Mar;40(3):110.e1-110.e9. doi: 10.1016/j.urolonc.2021.10.010. Epub 2021 Dec 11. Urol Oncol. 2022. PMID: 34906411 Free article.
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
Mertens LS, Claps F, Mayr R, Hodgson A, Shariat SF, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W, van der Kwast TH, Lotan Y, Allory Y, Downes MR, van Rhijn BWG. Mertens LS, et al. Among authors: pouessel d. Int J Surg Pathol. 2023 Apr;31(2):157-166. doi: 10.1177/10668969221095173. Epub 2022 Apr 24. Int J Surg Pathol. 2023. PMID: 35466737 Free article.
102 results